

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-2B1F6B00-AAF1-46C3-A99C-ACEC132879AA\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M6290\\_02\\_01](https://doi.org/10.31003/USPNF_M6290_02_01)  
DOI Ref: 1x0te

© 2025 USPC  
Do not distribute

## Aspirin Tablets

### DEFINITION

Aspirin Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of aspirin ( $C_9H_8O_4$ ). Tablets of larger than 81-mg size contain no sweeteners or other flavors. [NOTE—Tablets that are enteric-coated meet the requirements for [Aspirin Delayed-Release Tablets](#).]

### IDENTIFICATION

- **A.** The retention time of the aspirin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

**Change to read:**

- **B.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: **197K** ▲ (CN 1-MAY-2020)

**Sample:** Shake a quantity of finely powdered Tablets, equivalent to about 500 mg of aspirin, with 10 mL of alcohol for several min. Centrifuge the mixture. Pour off the clear supernatant, and evaporate it to dryness. Dry the residue under vacuum at 60° for 1 h.

**Acceptance criteria:** Meet the requirements

### ASSAY

#### • PROCEDURE

**Mobile phase:** 2 g/L of [sodium 1-heptanesulfonate](#) in a mixture of [acetonitrile](#) and [water](#) (15:85). Adjust with [glacial acetic acid](#) to a pH of 3.4.

**Diluent:** [Acetonitrile](#) and [formic acid](#) (99:1)

**Standard solution:** 0.5 mg/mL of [USP Aspirin RS](#) in *Diluent*

**Sample stock solution:** Nominally 5 mg/mL of aspirin prepared as follows. Transfer a quantity, equivalent to about 100 mg of aspirin from NLT 20 finely powdered Tablets, to a suitable container. Add 20.0 mL of *Diluent* and 10 glass beads. Shake vigorously for about 10 min, and centrifuge.

**Sample solution:** Nominally 0.5 mg/mL of aspirin in *Diluent* from *Sample stock solution*

#### Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

**Mode:** LC

**Detector:** UV 280 nm

**Column:** 4.0-mm × 30-cm; packing L1

**Flow rate:** 2 mL/min

**Injection volume:** 10 µL

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of aspirin ( $C_9H_8O_4$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of aspirin from the *Sample solution*

$r_S$  = peak response of aspirin from the *Standard solution*

$C_S$  = concentration of [USP Aspirin RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of aspirin in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

### PERFORMANCE TESTS

- [DISSOLUTION \(711\)](#)

**Medium:** 0.05 M acetate buffer, prepared by mixing 2.99 g of sodium acetate trihydrate and 1.66 mL of glacial acetic acid with water to obtain a total of 1000 mL of solution with a pH of  $4.50 \pm 0.05$ ; 500 mL

**Apparatus 1:** 50 rpm

**Time:** 30 min

**Standard solution:** A known concentration of [USP Aspirin RS](#) in *Medium*. Prepare the *Standard solution* at the time of use. [NOTE—A quantity of alcohol not to exceed 1% of the total volume of the *Standard solution* may be used to dissolve the Reference Standard prior to dilution with *Medium*.]

**Sample solution:** Pass a portion of the solution under test through a suitable filter, and dilute with *Medium*, if necessary.

#### Instrumental conditions

**Mode:** UV

**Analytical wavelength:** 265 nm

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Determine the percentage of the labeled amount of aspirin ( $C_9H_8O_4$ ) dissolved from UV absorbances at the isosbestic point of aspirin and salicylic acid at about 265 nm.

**Tolerances:** NLT 80% (Q) of the labeled amount of aspirin ( $C_9H_8O_4$ ) is dissolved.

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

#### IMPURITIES

- **LIMIT OF FREE SALICYLIC ACID**

**Mobile phase, Diluent, and Chromatographic system:** Proceed as directed in the Assay.

**System suitability solution:** 0.015 mg/mL of [USP Salicylic Acid RS](#) and 0.5 mg/mL of [USP Aspirin RS](#) in *Diluent*

**Standard solution:** 0.015 mg/mL of [USP Salicylic Acid RS](#) in *Diluent*

**Sample solution:** Use the *Sample stock solution* prepared as directed in the Assay.

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for salicylic acid and aspirin are about 0.7 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between salicylic acid and aspirin, *System suitability solution*

**Relative standard deviation:** NMT 4.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of salicylic acid ( $C_7H_6O_3$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of salicylic acid from the *Sample solution*

$r_S$  = peak response of salicylic acid from the *Standard solution*

$C_S$  = concentration of [USP Salicylic Acid RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of aspirin in the *Sample solution* (mg/mL)

**Acceptance criteria:** NMT 0.3%; for coated Tablets: NMT 3.0%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Preserve flavored or sweetened Tablets of 81-mg size or smaller in containers holding NMT 36 Tablets each.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Aspirin RS](#)

[USP Salicylic Acid RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ASPIRIN TABLETS	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 42(4)

**Current DocID:** GUID-2B1F6B00-AAF1-46C3-A99C-ACEC132879AA\_2\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M6290\\_02\\_01](https://doi.org/10.31003/USPNF_M6290_02_01)

**DOI ref:** [1x0te](#)

OFFICIAL